Onconetix, Inc. Announces 1-for-10 Reverse Stock Split
Onconetix, Inc. has announced a 1-for-10 reverse stock split approved by its Board of Directors, effective May 21, 2026. This decision follows stockholder approval at a special meeting to facilitate compliance with Nasdaq’s minimum bid price requirement. The split will reduce the number of outstanding shares from approximately 11.4 million to around 1.14 million, while maintaining the same ownership percentages for shareholders, with cash compensation for fractional shares.
CINCINNATI, Ohio, May 19, 2026 (GLOBE NEWSWIRE) — Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for oncology, today announced that its Board of Directors (the “Board of Directors” or “Board”) has approved a 1-for-10 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on May 21, 2026.